Memantine for dementia - McShane, R - 2006 | Cochrane Library Skip to Content Cookies Our
site uses cookies to improve your experience. You can find out more about our use of cookies …

Cochrane Page 1 Cochrane Library Cochrane Database of Systematic Reviews Memantine
for dementia (Review) McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L …

Background Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is
implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an …

Objectives: To assess the effects of rivastigmine on the core domains of Alzheimer9s
disease. Design: Prospective, randomised, multicentre, double blind, placebo controlled …

Background and Purpose—Based on the hypothesis of glutamate-induced neurotoxicity
(excitotoxicity) in cerebral ischemia, this study examined the efficacy and tolerability of …

Objective: To determine whether certain aspects of fluctuations reliably distinguish dementia
with Lewy bodies (DLB) from Alzheimer's disease (AD) and normal aging. Methods …

Summary Background Although treatments for Alzheimer's disease sometimes improve
cognition, functional ability, or behaviour compared with baseline levels, such improvements …

OBJECTIVE: It is well established that regional cerebral metabolic rates for glucose
assessed by [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) in …

Alzheimer's disease, which is characterized by progressive loss of memory and cognitive
function, affects 15 million people worldwide. The incidence increases steadily from 0.5 …

Objective: To evaluate the efficacy and safety of memantine in patients with mild to moderate
Alzheimer's disease (AD) receiving cholinesterase inhibitor (ChEI) treatment. Methods …